or the use of antibodies to block LILRB4 signalling impeded AML development. Thus, LILRB4 orchestrates tumour invasion pathways in monocytic leukaemia cells by creating an immunosuppressive microenvironment. LILRB4 represents a compelling target for the treatment of monocytic AML.
of AML cells to suppress T cells was reduced upon LILRB4 knockout (LILRB4 KO ) and was restored by forced expression of wild-type LILRB4 (LILRB4 KO -WT), but not by forced expression of a mutant LILRB4 with deleted intracellular domain (as LILRB4 KO -intΔ) ( Fig. 1d , Extended Data Fig. 2a-g) . Moreover, when wild-type THP-1 cells and human T cells were cultured in separate transwells, LILRB4-mediated T cell inhibition was also observed and could be reversed by anti-LILRB4 blocking antibodies (Extended Data Fig. 2h -p). Blocking LILRB4 resulted in an increase in T cell cytotoxicity and cytokine release (Extended Data Fig. 2q, u) . These in vitro data suggest that, instead of the extracellular domain 6 , the intracellular signalling of LILRB4 in AML cells is required for suppression of T cell activity.
Next, we used humanized mouse xenograft models and an immunocompetent mouse model to investigate LILRB4 function in immune checkpoint blockade. Subcutaneous implantation of THP-1 cells-but not of LILRB4 KO THP-1 cells-resulted in the development of AML in human T cell-reconstituted mice, and this was blocked by anti-LILRB4 treatment 7 (Extended Data Fig. 3a-i ). Doxycycline-induced deletion of LILRB4 in an established disseminated leukaemia model in humanized mice also impaired leukaemia development and restored T cells ( Fig. 1e , f, Extended Data Fig. 3j-l) . In addition, we subcutaneously implanted human LILRB4-expressing mouse C1498 AML cells (hLILRB4-C1498) into C57BL/6 mice to establish a syngeneic immunocompetent mouse model. To exclude the anti-tumour effects of Fc effector functions, we treated tumour-bearing mice with anti-LILRB4 with the Fc glycosylation site N297A mutation 8 . Blockade of LILRB4 effectively lowered tumour burden and prolonged survival; depletion of CD8 + T cells eliminated the anti-tumour effects of the anti-LILRB4 antibody (Extended Data Fig. 3m-r) . These results suggest that the tumour-supportive effect of LILRB4 depends on inhibition of host T cells. The anti-LILRB4 antibody treatment generated tumour-specific memory T cells (Extended Data Fig. 3s ). Similar results were obtained in the disseminated hLIL-RB4-C1498 syngeneic mouse model (Extended Data Fig. 3x-z) . Finally, blockade of LILRB4 reduced leukaemia development in xenografts derived from primary human monocytic AML cells ( Fig. 1g -i, Extended Data Fig. 4a ) and increased the number of engraftable autologous human T cells (Extended Data Fig. 4b ). Together, our in vitro and in vivo results
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indicate that LILRB4 signalling in monocytic AML cells suppresses T cell-mediated anti-tumour immunity.
One of the characteristic features of monocytic AML is enhanced extramedullary infiltration of tumour cells 9 . In addition to tumour shrinkage (Extended Data Fig. 3m ), antibody blockade of LILRB4 resulted in a decrease in leukaemic infiltration into internal organs, including bone marrow, liver and brain (Extended Data Fig. 3t -v). Although anti-LILRB4 antibody treatment did not reduce the size , mean ± s.e.m.). b, Comparison of surface expression of LILRB4 on normal monocytes and neoplastic monocytes from the same patients (n = 6 independent patients). MFI, mean fluorescence intensity. c, Autologous T cells (pT, patient T cells) isolated from a patient with monocytic AML (AML#19) or allogeneic T cells (nT, normal T cells) isolated from a healthy donor were incubated with irradiated LILRB4 + or LILRB4 − (B4 + or B4 − ) primary leukaemia cells from patient AML#19 (n = 3 biologically independent samples, mean ± s.e.m.; see Source Data). d, T cells (E, effector cells) isolated from healthy donors were incubated with indicated wild-type or modified irradiated THP-1 cells (T, target cells) in a cell-contact manner (n = 3 biologically independent samples, mean ± s.e.m.). WT, wild-type. e, f, Engraftment of human T cells and intravenously transplanted doxycycline (Dox)-inducible LILRB4 KO THP-1 cells (GFP + ) into NOD-SCID IL2Rγ-null (NSG) mice (n = 5 mice). LV, liver; BM, bone marrow; %, percentage of leukaemia cells (GFP + ) or human T cells (CD3 + ) in total mouse liver or bone marrow cells. g-i, Representative flow plots and quantification of per cent of CD45 + LILRB4 + cells in bone marrow from mice xenografted with human primary monocytic AML cells after treatment with anti-LILRB4 antibody or control IgG (n = 8 biologically independent samples). Experiment repeated for 16 independent patient samples with similar results (Extended Data Fig. 4a ). See Methods for definition of box plot elements in e-i. All P values from two-tailed Student's t-test. Fig. 3m ), treatment with anti-LILRB4 antibody did lead to a decrease in leukaemia cell infiltration into the liver (Extended Data Fig. 3w ). We hypothesized that, as well as inhibiting T cells, LILRB4 promotes leukaemia infiltration. To test this hypo thesis, we performed transendothelial migration and homing assays and monitored leukaemia infiltration relative to LILRB4 expression on leukaemia cells. Human AML THP-1 cells depleted of LILRB4 had lower transendothelial migration in vitro than cells that expressed LILRB4 ( Fig. 2a ). Deletion of LILRB4 reduced homing and engraftment of AML cells to haematopoietic organs (Fig. 2b, c) , and resulted in prolonged survival of xenografted mice ( Fig. 2d ) and delayed body weight loss ( Fig. 2e ). By contrast, forced expression of human LILRB4 in mouse AML C1498 or WEHI-3 cells had the opposite effects ( Fig. 2f -j, Extended Data Fig. 5a-e ). Antibody-mediated LILRB4 blockade in LILRB4-expressing AML cells had the same effects as LILRB4 knockout (Extended Data Fig. 5f -t). Leukaemia infiltration depended on LILRB4 expression and its intracellular signalling in leukaemia cells ( Fig. 2k ) but not the Fc effector functions of the antibody (Extended Data Fig. 5u , v). Furthermore, LILRB4 blockade reduced the infiltration ability of primary monocytic AML cells ( Fig. 2l -n, Extended Data Fig. 4c-e ). Our results are concordant with previous studies showing that the frequency of circulating LILRB4 + AML blasts is lower than that of LILRB4 − AML blasts 5 and that LILRB4 + chronic lymphocytic leukaemia cells are associated with lymphoid tissue involvement 10 . The bone marrow, liver, and brain-to which LILRB4 + AML cells tend to migrate-are known to have certain immune privileges [11] [12] [13] . Thus, LILRB4-mediated migration, which supports enhanced extramedullary infiltration of monocytic AML cells, may also contribute to immune evasion.
The blockade of immune inhibitory and migration functions of AML cells by anti-LILRB4 antibodies suggests that these functions of LILRB4 are regulated by extracellular mechanisms. Integrin-α v β 3 is the ligand for gp49B1, the mouse LILRB4 orthologue 14 . However, a variety of integrin-αβ complexes did not activate human LILRB4 reporter cells (Extended Data Fig. 6a, b ). Unexpectedly, human serum and mouse serum were capable of activating the LILRB4 reporter but not reporters for other LILRBs (Fig. 3a ). Through protein liquid chromatography fractionation followed by reporter assays and mass spectrometry we identified APOE, which specifically activated LILRB4 and mouse PirB reporters ( Fig. 3b , Extended Data Fig. 6c -j). Serum from wild-type mice, but not Apoe-null mice, activated the LILRB4 reporter ( Fig. 3c ). In addition, both liposome-reconstituted APOE protein (APOE-POPC) and lipid-free APOE activated LILRB4 reporter cells ( Fig. 3d ). Binding of APOE to THP-1 cells was significantly decreased by deletion of LILRB4 (Fig. 3e ). We confirmed specific binding of recombinant APOE to LILRB4 using microscale thermophoresis (MST), surface plasmon resonance (SPR) and bio-layer interferometry (Octet). The dissociation constant was 210 nM as determined by MST ( Fig. 3f , Extended Data Fig. 6k, l) . Mutagenesis studies showed that the N-terminal domain of APOE, and P35 and W106 in the first immunoglobulin domain and Y121 in the linker region between two immunoglobulin domains of LILRB4, are critical for APOE-mediated activation of LILRB4 ( Fig. 3g , h, Supplementary Table 2 , Extended Data Fig. 6m ).
The finding that APOE activates the immune inhibitory receptor LILRB4 is consistent with the immunosuppressive function of APOE 15, 16 . To determine whether suppression of T cells by LILRB4 depends on APOE, we examined proliferation of T cells co-cultured 10 -1 10 0 10 1 10 2 10 3 10 4 10 5 10 0 10 1 10 2 10 3 10 4 GFP hLILRB4:Apoe KO GFP hLILRB4:WT
Letter reSeArCH with control or APOE KO human AML cells. AML cells deficient in APOE restored proliferation of T cells and suppressed migration of leukaemia cells ( Fig. 3i , Extended Data Fig. 6n-t) . Moreover, the percentage of T cells in co-culture was lower when C1498 cells ectopically expressing LILRB4 were treated with wild-type mouse serum compared to those treated with Apoe KO mouse serum ( Fig. 3j , k). Addition of liposome-reconstituted APOE to a co-culture of mouse spleen cells and LILRB4-expressing AML cells decreased the T cell percentage ( Fig. 3l ). Furthermore, expression of LILRB4 increased infiltration of C1498 cells to bone marrow and liver in wild-type mice but not in Apoe KO recipients (Fig. 3m ). These data indicate that APOE activates LILRB4 on human monocytic AML cells to suppress T cell proliferation and support AML cell migration.
We sought to identify the signalling downstream of LILRB4 that is required for T cell suppression and leukaemia infiltration. The phosphatases SHP-1 (also known as PTPN6), SHP-2 (also known as PTPN11) and SHIP (also known as INPP5D) can be recruited to the intracellular domain of LILRB 2 . The level of phosphorylation of SHP-2, but not of SHP-1 or SHIP, was lower in LILRB4 KO AML cells than in wild-type cells ( Fig. 4a , Extended Data Fig. 7a ). Loss of SHP-2, but not loss of SHP-1 or SHIP, reversed T cell suppression by THP-1 cells ( Fig. 4b , Extended Data Fig. 7b-d) , and decreased short-term (20 h) and long-term (21 days) infiltration of THP-1 cells ( Fig. 4c, d ). Our results suggest that SHP-2 is a mediator of LILRB4 signalling.
Our ingenuity pathway analysis showed that the activity of the key transcription factors NFκB1 and RELA in the NFκB pathway 17 , which is positively regulated by SHP-2 18 , was strongly inhibited by loss of LILRB4 ( Fig. 4e , Supplementary Tables 3, 4 ). Consistently, phosphorylation of IKKα/β and levels of nuclear NFκB were decreased in LILRB4 KO AML cells ( Fig. 4f , g, Extended Data Fig. 7a ). Inhibition of NFκB signalling reversed T cell suppression and reduced AML cell infiltration in a LILRB4-dependent manner ( Fig. 4h , i, Extended Data Fig. 7e , f). Therefore the effects of LILRB4 are mediated through the NFκB pathway, which is particularly robust in monocytic AML among AML subtypes 19 .
Consistent with our result that AML cells inhibit T cell proliferation in transwells (Extended Data Fig. 2o , p), conditioned medium from wild-type THP-1 cells suppressed T cell activity but conditioned medium from LILRB4 KO cells did not ( Fig. 4j ). Among proteins that were present at higher levels in the conditioned medium of wild-type THP-1 cells than in that of LILRB4 KO cells (Extended Data Fig. 7g -i), the urokinase receptor uPAR is highly expressed by monocytic AML cells 20 . uPAR, an NFκB target, is known to promote cancer invasion, metastasis, survival and angiogenesis 21, 22 . The addition of recombinant uPAR decreased proliferation of T cells co-cultured with LILRB4 KO THP-1 cells in a dose-dependent manner ( Fig. 4k , Extended Data Fig. 7j ). This activity of uPAR is likely to be mediated by downstream effectors in AML cells because uPAR does not effectively decrease T cell proliferation directly (Extended Data Fig. 7k ).
The expression of arginase-1 (ARG1), as with that of uPAR, was lower in LILRB4 KO AML cells than in wild-type cells (Extended Data Fig. 7l , m). ARG1 inhibits T cell proliferation and can be upregulated by uPAR-mediated signalling 23, 24 , APOE 25 and NFκB 26 . We hypothesized that ARG1 is a key downstream effector of LILRB4-NFκB-uPAR signalling. ARG1 can be secreted by AML cells to inhibit T cell activity 27 . Recombinant ARG1 decreased T cell proliferation in co-culture with LILRB4 KO , APOE KO and SHP2 KO AML or primary AML cells ( Fig. 4l , Extended Data Fig. 7n-p) . Moreover, addition and overexpression of either uPAR or ARG1 rescued the migration ability of LILRB4 KO AML cells in vitro and in vivo, respectively (Extended Data Fig. 7q, Fig. 4m ). Together, our results indicate that LILRB4-SHP-2-NFκB-uPAR-ARG1 is a signalling pathway in monocytic AML cells (Extended Data Figs. 8, 9) that suppresses immune activity and supports leukaemia migration. 
Because LILRB4 is restrictively expressed on normal monocytic cells 2 , in which LILRB4 signalling may differ from that in leukaemia cells (Extended Data Fig. 9 ), and LILRB4 blockade did not significantly interfere with normal haematopoietic function (Extended Data Fig. 10 ), LILRB4 targeting may have minimal toxicity. Notably, LILRB4 is also expressed on certain other types of cancer, myeloid-derived suppressor cells, tolerogenic dendritic cells and tumour-associated macrophages 2,5,28-30 . Targeting LILRB4 may thus enable a combination of immunotherapy and targeted therapy in cancer treatment.
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Mice. C57 BL/6J and NOD-SCID IL2Rγ-null (NSG) mice were purchased from and maintained at the animal core facility of University of Texas Southwestern Medical Center (UTSW). Apoe KO (Apoe tm1Unc ) mice 31 were purchased from the Jackson Laboratory. Animal work described in this manuscript has been approved and conducted under the oversight of the UT Southwestern Institutional Animal Care and Use Committee (IACUC). For each experiment, the same sex-and agematched (4-8 weeks) mice were used and randomly allocated to each group; and for tumour size measurement and in vivo lumina imaging experiments, experimenters were blinded to the treatment conditions of the mice. The minimum number of mice in each group was calculated based on results from our prior relevant studies [32] [33] [34] [35] [36] . For the subcutaneous tumour model, the tumour size was calculated as (width × width × length) cm 3 . The maximal tumour measurement permitted by UTSW IACUC is 2 cm in diameter. In none of the experiments were these limits exceeded (see Source Data). We complied with all relevant ethical regulations and used approved animal study protocols. Cell culture. 293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37 °C in 5% CO2 and normal O 2 . Human umbilical vein/vascular endothelium cells (HUVECs) (ATCC, CRL-1730) were cultured in endothelial cell growth medium plus growth factor, cytokines and supplements (EGM-BulletKit, Lonza) at 37 °C in 5% CO2 and normal O 2 . Human monocytic AML cells (THP-1 (ATCC, TIB-202), MV4-11 (ATCC, CRL-9591), and U937 (ATCC, CRL-1593.2)) and mouse AML cells (WEHI-3 (ATCC, TIB-68)) were cultured in Roswell Park Memorial Institute (RPMI) 1640 supplemented with 10% FBS at 37 °C in 5% CO 2 and normal O 2 . Mouse AML cells (C1498 (ATCC, TIB-49)) were cultured in DMEM supplemented with 10% FBS at 37 °C in 5% CO 2 and normal O 2 . All cell lines were routinely tested using a mycoplasma-contamination kit (R&D Systems). Primary human leukaemia cells. Primary human AML and B-cell acute lymphoblastic leukaemia (B-ALL) samples were obtained from the tissue banks at UTSW and University of Texas MD Anderson Cancer Center (MDACC). Informed consent was obtained under protocols reviewed and approved by the Institutional Review Board at UTSW and MDACC (IRB STU 122013-023 by UTSW and LAB10-0682 by MDACC). The UTSW cohort included 105 patients with AML representative of AML subtypes by the French-American-British (FAB) classification, acute myeloblastic leukaemia with minimal maturation (M1, n = 9), acute myeloblastic leukaemia with maturation (M2, n = 34), acute promyelocytic leukaemia (M3, n = 10), acute myelomonocytic leukaemia (M4, n = 34), acute monocytic leukaemia (M5, n = 25), acute erythroid leukaemia (M6, n = 2), and acute megakaryoblastic leukaemia (M7, n = 1) and patients with undifferentiated leukaemia (AUL; n = 1) and transient myeloproliferative disorder (TAM; n = 2) (Supplementary Table 1 ). Samples were frozen in FBS with 10% DMSO and stored in liquid nitrogen. Primary leukaemia samples used in patient-derived xenografts (PDXs), co-culture, short-term infiltration assay and western blotting were summarized in Supplementary Table 5 . We have complied with all relevant ethical regulations with approved study protocols. Human normal monocytes and macrophages. Human normal monocytes (CD14 + cells) were isolated by the AutoMACS Pro Separation System (Miltenyi Biotech) from the mononuclear cells fraction of normal peripheral blood. In brief, buffy coat was purchased from Interstate Blood Bank and the mononuclear cell layer was separated by Ficoll Hypaque (17144003, GE Lifesciences) density gradient separation. Mononuclear cells were treated with red blood cell lysis buffer to remove red blood cells and then incubated with CD14 microbead-conjugated antibody (130-050-201, Miltenyi Biotech) for 15 min at 4 °C. CD14-positive cells were then isolated using the positive selection program according to the manufacturer's protocol. One million CD14 + cells were plated in macrophage culture medium, Iscove's modified Dulbecco's medium (IMDM) (12440053, Thermo Fisher) supplemented with 10% human AB serum (MT35060CI, Fisher Scientific), 1% NEAA (11-140-050, Fisher), 2 µM l-alanine-l-glutamine (SH3003402, Fisher), per each well of a 6-well plate and cultured for 7 days. After incubation, most of the cells were adherent to the plastic surface and stained positive for CD14 and other markers specific for macrophages. TCGA analyses. Data were obtained from the TCGA acute myeloid leukaemia database (version: 16 August 2016). The patients were classified into AML subtypes (FAB classification) M0 (undifferentiated acute myeloblastic leukaemia) (n = 16), M1 (n = 42), M2 (n = 39), M3 (n = 16), M4 (n = 35), M5 (n = 18), M6 (n = 2), M7 (n = 3); two cases were not classified by subtype. The mRNA levels of indicated genes were determined by RNA-seq (polyA+ IlluminaHiSeq). RESMnormalized counts are reported, and data were analysed and visualized with UCSC Xena (https://xena.ucsc.edu/). For analysis of overall survival, 160 patients with available survival data were separated into three groups based on whether they had high, moderate or low gene expression and then analysed by Xena Kaplan-Meier plot (http://xena.ucsc.edu/survival-plots/). Flow cytometry. Primary antibodies including anti-human CD45-PE (BD Pharmingen, HI30, 1:100), CD45-FITC (BD Pharmingen, HI30, 1:100), CD45-APC (BD Pharmingen, HI30, 1:100), anti-human CD34-FITC (BD Pharmingen, 55582, 1:100), anti-human CD19-PE (eBioscience, HIB19, 1:100), anti-human CD20-PE (BD Pharmingen, 555623, 1:100), anti-human CD11b-APC (eBioscience, ICRF44, 1:100), anti-human LILRB4-APC (eBioscience, ZM4.1, 1:100), anti-human LILRB4-PE (Biolegend, ZM4.1, 1:100), anti-human CD14-APC (eBioscience, 61D3, 1:100), anti-human CD33-APC (Biolegend, P67.6, 1:100), anti-human CD4-APC (eBioscience, RPA-T4, 1:100), anti-human CD3-FITC (BioLegend, HIT3a, 1:100), anti-human CD3-Pacific blue (BD Pharmingen, SP34-2, 1:100) anti-human CD8-PE (BD Pharmingen, 555367, 1:100), anti-human CD28-APC (eBioscience, CD28. , and IgG isotype-control-APC (eBioscience, P3.6.2.8.1, 1:400) antibodies were used. Cells were run on either Calibur for analysis or FACSAria for analysis and sorting. Flow data were analysed by Flowjo software. For analysis of human haematopoietic engraftment in NSG mice, a previously published protocol was followed 33,35,37 . Propidium iodide (PI) staining was used to exclude dead cells in analysis and sorting. For intracellular staining, we followed the two-step protocol for fixation/methanol from eBioscience. In brief, human primary AML cells were stained for surface expression of LILRB4 (anti-LILRB4-Alexa Fluor 647, Biolegend, ZM4.1, 1:100) and CD33 (anti-human CD33-FITC, Biolegend, HIM3-4, 1:100) and fixable cell viability dye eFluor 450 (Bioscience, Cat#65-0863-14, 1:100) followed by fixation (IC fixation buffer, eBioscience, Cat#00-8222) and methanol treatment. After that, cells were stained for intracellular antigens by anti-p-SHP-2 (Y580)-PE (Cell Signaling, Cat#13328S, 1:100), anti-pIKKα/β (S176/180) (16A6) (Cell Signaling, Cat#2697, 1:100), anti-NFκB (S529)-PE (eBioscience, B33B4WP, 1:100), anti-uPAR-PE (Biolegend, VIM5, 1:100), anti-arginase-1 (D4E3M) (Cell Signaling, Cat#93668, 1:100), rabbit IgG isotype control-PE (Cell Signaling, Cat#5742, 1:100), mouse IgG isotype control-PE (eBioscience, m2a-15F8, 1:100) and anti-rabbit IgG-PE (Jackson Immunoresearch Laboratory, Cat#111-116-144, 1:400) for flow cytometry analysis. Virus construction and infection. For retrovirus packaging, plasmid constructs XZ201-IRES-GFP and XZ201-human LILRB4 (hLILRB4)-IRES-GFP were mixed with PCL-ECO (2:1), followed by transfection into 293T cells using Lipofectamine 2000 (Invitrogen). For lentivirus packaging, CRISPR-Cas-9-based guide RNA (gRNA) constructs and other constructs for gene overexpression, including pLentiLox3.7-luciferase-IRES-GFP, ZsGreen-hLILRB4 and ZsGreen-hLILRB4-intΔ, pLVX-PLAUR-IRES-tdTomato and pLVX-ARG1-IRES-tdTomato were mixed with psPAX2 and pMD2.G (Addgene) at a ratio of 4:3:1 and transfected into 293T cells using Lipofectamine 2000 (Invitrogen). Virus-containing supernatant was collected 48-72 h post-transfection and used for infection as previously described 38 . CRISPR-Cas9-based gene knockout in AML cells. Human AML cells were infected with doxycycline-inducible Cas9-expressing lentivirus (pCW-Cas9, Addgene 50661). After 1 µg/ml puromycin selection, surviving cells were infected with sgRNA-expressing lentivirus, produced by the plasmid modified from pSLQ1651 (Addgene 51024) by replacing the puro-mcherry with GFP for sorting. Scramble control sgRNA (sgRNA 5′-GAACGACTAGTTAGGCGTGTA-3′), LILRB4 targeting sgRNA (sgRNA1 5′-TGTTACTATCGCAGCCCTGT-3′; sgRNA2 5′-GTAGGTCCCCCCGTGCACTG-3′; sgRNA3 5′-CCTGTGACCTCAGTGCAC GG-3′), APOE targeting sgRNA (sgRNA1 5′-CTT TTGGGATTACCTGCGC-3′; sgRNA2 5′-AACTGGCACTGGGTCGCTTT-3′), SHP1 targeting sgRNA (sgRNA1 5′-TAAGACCTACATCGCCAGCC-3′; sgRNA2 5′-GAAGAACTTGCACCAGCG TC-3′), SHP2 targeting sgRNA (sgRNA1 5′-GAGACTTCACACTTTCCGTT-3′; sgRNA2 5′-TACAGTACTACAACTCAAGC-3′), SHIP targeting sgRNA (sgRNA1 5′-CACGCAGAGCGCGTATGCCC-3′; sgRNA2 5′-TGGCAA CATCACCCGCTCCA-3′) which were designed by an online tool (http://crispr. mit.edu), were cloned into the sgRNA plasmid, individually. After being treated with 1 µg/ml doxycycline (Sigma, Cat#PHR1789) for 1 week, these cells were stained with anti-LILRB4 antibody and the LILRB4 negative cells were sorted as LILRB4 KO cells. For APOE KO , SHP1 KO , SHP2 KO and SHIP KO cells, GFP + cells were sorted into a 96-well plate as a single cell per well. After cell expansion, knockout cells were verified by western blotting. For in vivo induction of CRISPR-Cas9 to achieve gene knockout, we fed mice with doxycycline as described 39 . In brief, 7 days after Cas9/LILRB4-sgRNA-transfected THP-1 cell implantation, mice were treated with 2 mg per mouse of doxycycline via gavage daily for 5 days to achieve
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Cas9 expression in engrafted leukaemia cells. The knockout was validated by flow cytometry. Leukaemia cell and T cell co-culture assay. In the co-culture assay, human T cells (5 × 10 4 per well) isolated from health donor peripheral blood (PB009-1-0, Allcells) were mixed with irradiated (28 Gy) indicated human leukaemia cells in a U-bottom 96-well plate. For non-contact co-culture of T cells with leukaemia cells, leukaemia cells were cultured in the upper chamber of transwell inserts (pore size, 3 µM, #09-761-80, Thermo Fisher) in U-bottom 96 well-plates. T cells isolated from healthy donors were placed in the lower chambers of a 96-well transwell plate. Irradiated indicated leukaemia cells (E:T ratio = 2:1 if not indicated) were added to the upper chambers and treated with indicated antibodies, proteins and reagents. After culture with anti-CD3/CD28-coated beads (11161D, Thermo Fisher) and 50 U/ml rhIL-2 for 5-7 days, representative cells were photographed using an inverted microscope, and T cells were stained with anti-CD3 antibodies and analysed by flow cytometry.
For primary AML or B-ALL samples, patient leukaemia cells were sorted as CD33 + and CD19 + for AML and B-ALL, respectively. These leukaemia cells were cultured with autologous CD3 + T cells from the same patient or allogeneic T cells from a health donor (E:T ratio = 2:1). After culture with anti-CD3/CD28-coated beads (11161D, Thermo Fisher) and 50 U/ml rhIL-2 for 14 days, representative cells were photographed using an inverted microscope, and T cells were stained with anti-CD3, anti-CD4 and anti-CD8 antibodies and analysed by flow cytometry.
For cytotoxicity assay, human CD8 + T cells (5 × 10 4 per well) isolated from peripheral blood mononuclear cells (PBMCs) from a healthy donor were stimulated with anti-CD3/CD28/CD137-coated beads (11163D, Thermo Fisher) for 2 days in a 96-well plate. Then, indicated 5 × 10 3 leukaemia cells and 50 to 500 µg/ml anti-LILRB4 antibodies or control IgG were added. Cell numbers were determined on day 7 in triplicate wells. Alternatively, indicated leukaemia cells in indicated E:T ratios were cultured with T cells for 4-6 h in triplicate wells. Anti-CD3 and anti-CD8 were used to detect human CTL cells; indicated live THP-1 cells were positive for GFP and negative for PI. Cell supernatants from co-cultures of stimulated CTL cells and THP-1 cells treated with anti-LILRB4 or IgG were used to examine cytokine production using human cytokine arrays (AAH-CYT-6, RayBiotech).
For co-culture of mouse leukaemia and T cells, spleen cells from wild-type C57BL/6 mice were co-cultured with 2.5 × 10 4 irradiated (28 Gy) mouse leukaemia C1498 cells in a U-bottom 96 well-plate for 60 h. Anti-CD3/CD28-coated beads (11452D, Thermo Fisher), 50 U/ml recombinant human IL-2, and 5% serum from wild-type C57BL/6 mice or from Apoe KO mice were added to the medium. In some experiments, 50 µg/ml lipid-bound APOE proteins (APOE-POPC) were added to the medium. The lipidation of APOE recombinant protein was conducted as described 40 . Transendothelial migration assays. To measure the ability of AML cells to migrate through endothelial cells, 3 × 10 5 HUVECs were cultured on a transwell membrane (pore size 8 µm). After 3 days, 1 × 10 5 indicated leukaemia cells were seeded in the upper chamber. In indicated experiments, leukaemia cells were treated with antibodies or proteins in the upper chamber. After 18 h, cells in the lower chamber were counted. Short-term infiltration assay of leukaemia cells and homing assay of haematopoietic stem/progenitor cells. Cells (5 × 10 6 cells per mouse) were injected intravenously into NSG mice. Animals were treated with 10 mg/kg of anti-LILRB4 antibodies or control IgG immediately after injection of leukaemia cells. Mice were euthanized by CO 2 asphyxiation and death was assured by cervical dislocation after 20 h. Peripheral blood, bone marrow, liver and spleen were collected, and single-cell suspensions were examined by flow cytometry. CFSE, GFP or indicated markers such as anti-human CD45 and anti-human CD33 were used to detect target leukaemia cells in indicated experiments. Numbers of leukaemia cells in recipient liver, spleen and bone marrow are reported as a ratio relative to cell numbers in peripheral blood.
To test the infiltration ability of mouse leukaemia cells, 5 × 10 6 C1498 GFP hLILRB4 cells or C1498 GFP cells were injected intravenously into wild-type C57BL/6 or Apoe-null mice. Mice were euthanized after 20 h. GFP was used to detect leukaemia cells by flow cytometry. The number of leukaemia cells in recipient liver, spleen and bone marrow were normalized to numbers in peripheral blood, and are reported as a ratio.
To test the homing ability of haematopoietic stem/progenitor cells (HSPCs), 1 × 10 7 human cord blood mononuclear cells were injected intravenously into an NSG mouse. Mice were treated with 10 mg/kg of anti-LILRB4 antibodies or control IgG immediately after injection of mononuclear cells and were killed after 20 h. Anti-human CD45 and anti-human CD34 were used to detect human HSPCs by flow cytometry. Similarly, to test the infiltration ability of normal human monocytes, 5 × 10 6 CD14-positive selected monocyte from health donor PBMC were labelled by CFSE and injected intravenously into an NSG mouse. Mice were treated with 10 mg/kg of anti-LILRB4 antibodies or control IgG immediately after injection of monocytes and were euthanized after 20 h. CFSE-positive cells were analysed by flow cytometry. Innate immune cell depletion. NK cell depletion was done by intraperitoneal injection of 50 µl anti-asialo GM1 antibodies (CL8955, Cedarlane) 3 days before leukaemia cell implantation, which resulted in >90% depletion of CD45 + CD49b + NK cells in the circulation of NSG mice. Macrophages were depleted by treating NSG mice with clodronate (dichloromethylene bisphosphonate) liposomes (SKU8909, Clodrosome) (200 µl of stock solution 3 days before leukaemia cell implantation), resulting in >70% depletion of CD45 + CD11b + F4/80 + macrophages in the circulation of NSG mice. NSG mice were rendered neutropenic by intraperitoneal injection of 200µg anti-Ly-6G mAb (BP0075-1, Bioxcell) on days -3, -2, -1, and 0 after leukaemia cell implantation, resulting in >80% depletion of CD45.1 + CD11b + CD11cneutrophils in the circulation of NSG mice. Human AML xenografts. Xenografts were performed essentially as described 2,3,6,7 . In brief, 6-8-week-old NSG mice were used for transplantation. Human leukaemia cells (1 × 10 6 ) were resuspended in 200 µl PBS for each mouse intravenous injection. Mice were immediately given 10 mg/kg of anti-LILRB4 antibodies or control IgG intravenously. Three to four weeks after transplantation, the peripheral blood, bone marrow, spleen and liver were assessed for engraftment. Leukaemia growth was monitored over time by luminescence imaging (maximum, 3 × 10 8 p/sec/cm 2 / sr; min, 5 × 10 6 p/sec/cm 2 /sr). For survival curve experiments, death was recorded when moribund animals were euthanized. For primary PDXs, each NSG mouse was given 5-10 × 10 6 human primary peripheral blood or bone marrow mononuclear cells, which contain leukaemia cells and other normal compartments such as normal haematopoietic stem progenitor cells and autologous T cells, via tail-vein injection. Mice were immediately given 10 mg/kg of anti-LILRB4 antibodies or control IgG intravenously and were treated twice a week until euthanization. For AML#11, mice were given 10 mg/kg of anti-LILRB4 antibodies or control IgG intravenously 7 days after leukaemia cell implantation and were treated twice a week until euthanization. Leukaemia growth was monitored over time by flow cytometry of human cells in peripheral blood. The presence of more than 1% of human leukaemia cells in mouse tissue was considered successful engraftment of primary AML cells. One to four months after transplantation, the peripheral blood, bone marrow, spleen, and liver were assessed for engraftment.
For the human PBMC (hPBMC)-humanized model, 1 × 10 7 hPBMCs were injected intravenously into each NSG mouse. Three weeks after implantation, mice had 30 to 50% engraftment of human T cells. At 3 weeks post implantation, 1 × 10 6 human AML THP-1 cells, including wild-type or LILRB4 KO THP-1 cells or THP-1 cells stably expressing luciferase (THP-1-Luc-GFP cells) were subcutaneously implanted. Mice were immediately given 10 mg/kg of anti-LILRB4 antibodies or control IgG intravenously and were treated twice a week until euthanization. Tumour growth was monitored over time by luminescence imaging (maximum, 1 × 10 8 p/sec/cm 2 /sr; min, 5 × 10 6 p/sec/cm 2 /sr). Tumour sizes were determined by caliper measure (width × width × length). For the inducible LILRB4 knockout experiment, 1 × 10 6 Cas9/LILRB4-sgRNA-transfected THP-1 cells were injected intravenously into each NSG mouse, immediately followed by intravenous injection of 0.5 × 10 6 isolated human normal T cells from health donors. Seven days after THP-1 and T cell implantation, mice were treated with 2 mg per mouse of doxycycline via gavage daily for 5 days to achieve Cas9 expression in engrafted THP-1 cells. At 3 weeks post implantation, the peripheral blood, bone marrow, spleen, and liver were assessed for engraftment.
For the human cord blood (hCB) xenograft model, 2 × 10 4 CD34 + hCB cells were injected intravenously into each NSG mouse. Six weeks after implantation, mice had 10 to 50% engraftment of human cells. THP-1 cells (1 × 10 6 ) that stably express luciferase were intravenously implanted. Mice were immediately given 10 mg/kg of anti-LILRB4 antibodies or control IgG intravenously. Tumour growth was monitored over time by luminescence imaging (maximum, 1 × 10 8 p/sec/ cm 2 /sr; min, 5 × 10 6 p/sec/cm 2 /sr). Lineages of human normal blood cells were analysed by flow cytometry. Mouse AML allograft. The procedure for mouse AML allografts was similar to that for human AML xenografts. In brief, 6-8-week-old wild-type C57BL/6 mice were used for transplantation. Mouse leukaemia cells (1 × 10 6 ) expressing human LILRB4 were resuspended in 200 µl PBS for each mouse for intravenous or subcutaneous implantation. Mice were given 10 mg/kg of anti-LILRB4-N297A antibodies or control IgG intravenously 7 days after leukaemia cell implantation and were treated twice a week until euthanization. Three weeks after transplantation, the peripheral blood, bone marrow, spleen and liver were assessed for engraftment. For subcutaneously implanted mice, tumour sizes were determined by caliper measure (width × width × length). For survival curve experiments, death was recorded when moribund animals were euthanized. For CD8 + T depletion, 10 mg/kg anti-CD8 antibodies (YTS 169.4.2, Bioxcell) were injected intravenously 3 days after leukaemia cell implantation and mice were treated for an additional 2 times every 3 days. To determine whether anti-LILRB4 antibody treatment generated tumour-specific memory T cells against the tumour or against LILRB4,
we conducted adoptive transfer of spleen cells (5 × 10 6 cells per mouse) from anti-LILRB4 treated mice into normal recipient C57BL/6 mice. Four out of five transplanted mice rejected the control C1498-GFP mouse leukaemia cells, and these mice were not susceptible to rechallenge with threefold higher numbers (3 × 10 6 cells per mouse) of C1498-GFP leukaemia cells. Of 5 mice that received adoptive transfer of spleen cells from naive mice, none rejected the control C1498-GFP mouse leukaemia cells. Chimeric receptor reporter assay. We constructed a stable chimeric receptor reporter cell system as described 3, 4 to test the ability of a ligand to bind to the ECD of individual LILRBs, PirB, gp49B1 and LILRB4 site mutants and to trigger the activation or inhibition of the chimerically fused intracellular domain of paired immunoglobulin-like receptor β, which signals through the adaptor DAP-12 to activate the NFAT promoter. If an agonist or antagonist binds the ECD and activates or suppresses the chimeric signalling domain, an increase or decrease, respectively, in GFP expression is observed. A competition assay was used to screen LILRB4 blocking antibodies. In brief, APOE proteins (CI02, Novoprotein; 10 µg/ml) or human AB serum (10%, diluted in PBS) were pre-coated onto 96-well plates at 37 °C for 3 h. After two washes with PBS, 2 × 10 4 LILRB4 reporter cells were seeded in each well; meanwhile, indicated anti-LILRB4 antibodies were added into the culture medium. After 16 h, the percentage of GFP + reporter cells was analysed by flow cytometry. The threshold of activation is 2 times that of negative control treatment. Bio-layer interferometry. Binding interaction analyses between LILRB4-Fc and APOE2, APOE3 or APOE4 were performed on the Octet RED96 (ForteBio, Pall). All interaction studies were performed with the protein A dip-and-read biosensors (ForteBio). All binding experiments were performed using the Octet Red and kinetics buffer at 30 °C. LILRB4-Fc coated biosensors (25 µg/ml LILRB4-Fc was loaded for 420 s) were washed in kinetics buffer before monitoring of association (300 s) and dissociation (600 s) of APOEs. Background wavelength shifts were measured from reference sensors that were loaded only with LILRB4-Fc. Surface plasmon resonance. Biacore 2000 and CM5 chips were used to analyse binding of recombinant APOEs to the LILRB4 extracellular domain fused to hFc as described 2 . Recombinant protein A (Pierce) was pre-immobilized in two flow cells using the amine-coupling kit from GE. LILRB4-hFc was injected into one of the flow cells to be captured by protein A. Each binding sensorgram from the sample flow cell, containing a captured LILRB4-hFc, was corrected for the protein A-coupled cell control. Following each injection of an antigen solution, which induced the binding reaction, and the dissociation period during which the running buffer was infused, the protein A surface was regenerated by injection of regeneration solution containing 10 mM Na 3 PO 4 (pH 2.5) and 500 mM NaCl. All captured LILRB4-hFc, with and without APOE bound, was completely removed, and another cycle begun. All measurements were performed at 25 °C with a flow rate of 30 µl/min. Microscale thermophoresis. MST experiments were performed on a Monolith NT.115 system (NanoTemper Technologies) using 80% LED and 20% IR-laser power. Laser on and off times were set at 30 s and 5 s, respectively. Recombinant LILRB4-ECD protein (SinoBio) was labelled with 4488-NHS (NanoTemper Technologies) and applied at a final concentration of 5.9 nM. A twofold dilution series was prepared for unlabelled His-APOE (CI06, Novoprotein) in PBS, and each dilution point was similarly transferred to LILRB4-ECD solution. The final concentrations of His-APOE ranged from 0.36 nM to 12 µM. Samples were filled into standard-treated capillaries (NanoTemper Technologies) for measurement. Western blotting and co-immunoprecipitation. Whole cells were lysed in Laemmli sample buffer (Sigma-Aldrich) supplemented with protease inhibitor cocktail (Roche Diagnostics). Samples were separated on SDS-PAGE gels (Bio-Rad) and transferred onto nitrocellulose membranes (Bio-Rad) for protein detection. Primary antibodies including anti-SHP-1 (Cell Signaling, 3759, 1:1,000), anti-phospho-SHP-1 Tyr564 (Cell Signaling, 8849, 1:500), anti-phospho-SHP-1 Tyr564 (Invitrogen, PA537708, 1:500), anti-SHP-2 (Cell Signaling, 3397, 1:1,000), anti-phospho-SHP-2 Tyr580 (Cell Signaling, 3703, 1:500), anti-SHIP1 (Cell Signaling, 2727, 1:1,000), anti-phospho-SHIP1 Tyr1020 (Cell Signaling, 3941, 1:500), anti-NFκB p65 (Cell Signaling, 8242, 1:1,000), anti-IKKα (Cell Signaling, 11930, 1:1,000), anti-IKKβ (Cell Signaling, 8943, 1:1,000), anti-phospho-IK-Kα/β Ser176/180 (Cell Signaling, 2697, 1:500), anti-IκBα (Cell Signaling, 4814, 1:1,000), anti-phospho-IκBα Ser32 (Cell Signaling, 2859, 1:500), anti-Lamin-B2 (Cell Signaling, 12255, 1:1,000), anti-arginase-1 (Cell Signaling, 9819, 1:1,000), anti-uPAR (Invitrogen, MON R-4-02, 1:500), anti-LILRB4 (Santa Cruz, sc-366213, 1:200), anti-APOE (Creative Diagnostics, DCABH-2367, 1:250), anti-β-actin (Sigma-Aldrich, A2066, 1:1,000) and anti-α-tubulin (Sigma-Aldrich, MABT205, 1:1,000), as well as horseradish peroxidase conjugated secondary antibodies (Cell Signaling, 7074, 1:1,000, and 7076, 1:1,000) and chemi-luminescent substrate (Invitrogen), were used. Specific cellular compartment fractionations were carried out using the NE-PER nuclear/cytoplasmic extraction kit (Thermo Fisher, 78833) or the plasma membrane protein extraction kit (Abcam, ab65400). Proteins from plasma membrane fraction were further incubated with anti-LILRB4 antibodies and dynabeads protein A (Thermo Fisher, 10001D) for further immunoprecipitation and western blotting. Immunohistochemistry. Haematoxylin staining and immunostaining were performed on paraffin sections of tumours. Antibodies used were against LILRB4 (laboratory produced, 1:100), CD3 (Abcam, ab16669, 1:100), PD-1 (Thermo Fisher, J116, 14-9989-82, 1:100) and arginase-1 (Cell Signaling, 9819S, 1:100). The images were visualized using the Hamamatsu NanoZoomer 2.0-HT (Meyer instruments) and viewed in NPDview2 software (Hamamatsu). Cytokine antibody array and arginase activity assay. To examine the secreted protein from leukaemia cells, conditioned media were applied to a human cytokine antibody array (AAH-CYT-1000, RayBio) for the semiquantitative detection of 120 human proteins. Image J (NIH) was used for quantification. Arginase activity was determined in condition medium of indicated leukaemia cells by a QuantiChrom Arginase assay kit (DARG100, BioAssay system). RNA-seq analysis. RNA was purified from sorted cells with Qiagen RNeasy Mini Kit and then reverse-transcribed with SuperScript III Reverse Transcriptase (Invitrogen) according to the manufacturer's instructions. RNA-seq was performed at the UTSW Genomics and Microarray Core Facility. The cDNA was sonicated using a Covaris S2 ultrasonicator, and libraries were prepared with the KAPA High Throughput Library Preparation Kit. Samples were end-repaired, and the 3′ ends were adenylated and barcoded with multiplex adapters. PCR-amplified libraries were purified with AmpureXP beads and validated on the Agilent 2100 Bioanalyzer. Before being normalized and pooled, samples were quantified by Qubit (Invitrogen) and then run on an Illumina Hiseq 2500 instrument using PE100 SBS v3 reagents to generate 51-bp single-end reads. Before mapping, reads were trimmed to remove low-quality regions in the ends. Trimmed reads were mapped to the human genome (HM19) using TopHat v2.0.1227 with the UCSC iGenomes GTF file from Illumina.
Methods for data normalization and analysis are based on the use of 'internal standards' that characterize some aspects of the system's behaviour, such as technical variability, as presented elsewhere. Genes with log 2 (fold change) > 2, P < 0.01 and RPKM >0.1 were deemed to be significantly differentially expressed between the two conditions and were used for pathway analysis and upstream transcription factor analysis. Pathway analysis was conducted using the DAVID (https://david.ncifcrf.gov/tools.jsp). Upstream transcription-factor analysis was conducted using QIAGEN's Ingenuity tool (http://www.ingenuity.com/). Molecular docking of LILRB4 with APOE. Docking of LILRB4 with APOE was performed on ZDOCKpro module of the Insight II package. The general protocol for running ZDOCK includes two consecutive steps of calculation described as geometry search and energy search, running in program ZDOCK and RDOCK, respectively. LILRB4 crystal structure (3P2T) and APOE3 structure (2L7B) were obtained from the Protein Data Bank database. The top 50 ZDOCK poses were submitted to RDOCK refinement. Poses with high scores in both ZDOCK and RDOCK were selected as candidate complex for LILRB4-APOE interaction analysis (Supplementary Table 2 ). Statistical analyses. Representative data from four independent experiments or indicated independent samples are presented as dot plots (means ± s.e.m.) or as box-and-whisker plots (median values (line), 25th-75th percentiles (box outline) and minimum and maximum values (whiskers)). Statistical significance for two-sample comparisons was calculated by two-tailed Student's t-test. Statistical significance for survival was calculated by the log-rank test. The multivariate analysis of TCGA data was analysed by Cox regression. The difference was considered statistically significant if P < 0.05. NS, not significant; exact P values are shown. Pearson's correlation analyses were performed with RStudio software (the R Foundation). Fig. 1c (scale bar, 100 µm) . c, Loss of LILRB4 on THP-1 cells does not affect cell proliferation (n = 3 biologically independent samples with mean and s.e.m.). d, Examination of LILRB4 expression on cell surface of LILRB4 KO MV4-11 cells by flow cytometry. e, f, Loss of LILRB4 on MV4-11 cells reduces T cell suppression. T cells isolated from healthy donors incubated in the lower chambers of a 96well transwell plate with irradiated MV4-11 cells (E:T of 2:1) in the upper chamber separated by a membrane with 3-µm pores. After culture with anti-CD3/CD28-coated beads and rhIL-2 for 7 days, representative cells were photographed using an inverted microscope (scale bar, 100 µm) (e) and T cells were stained with anti-CD3 and analysed by flow cytometry (f). n = 4 biologically independent samples. g, Loss of LILRB4 on MV4-11 cells does not affect cell proliferation (n = 3 biologically independent samples with mean and s.e.m.). h, i, T cells (E, effector cells) isolated from healthy donors were incubated with indicated irradiated THP-1 cells (T, target cells) without direct contact in transwells for 2 days. E:T = 2:1. T cells were treated with BrdU for 30 min followed by BrdU and 7-AAD staining for flow cytometry analysis. Representative flow cytometry plots are shown in h and the cell cycle status is summarized in i. T control, T cells cultured without THP-1 cells. n = 3 biologically independent samples with mean and s.e.m. j, k, T cells (E, effector cells) isolated from healthy donors were stained with CFSE and incubated with indicated irradiated THP-1 cells (T, target cells) without direct contact in transwells for 2 days. A representative flow cytometry plot is shown in j and the percentages of proliferating T cells indicated by CFSE-low staining is shown in k. n = 3 biologically independent samples with mean and s.e.m. l, LILRB4 increases PD-1 expression on T cells in coculture of leukaemia cells and T cells. T cells (E, effector cells) isolated from healthy donors were incubated with indicated irradiated THP-1 cells (T, target cells) in a non-contact manner for 5 days. E:T = 2:1. T cells were stained with anti-LAG-3, anti-TIM-3, anti-TIGIT, anti-PD-1 and anti-FasL antibodies for flow cytometry analysis. Representative flow cytometry plots and the mean of fluorescence intensities, at the right-upper corner (black, WT; red, KO), are shown. Experiments were performed three times with similar results. m, n, Anti-LILRB4 antibody had no effect on proliferation of THP-1 cells (m) or T cells (n). m, The growth of THP-1 cells during 7 days treatment with IgG or anti-LILRB4 antibody (n = 3 biologically independent samples with mean and s.e.m.). n, The numbers of human primary T cells after 5 days treatment with IgG or anti-LILRB4 antibody in vitro (n = 3 biologically independent samples with mean and s.e.m.). o, p, Primary T cells and irradiated THP-1 cells (E:T ratio, 2:1) were placed in the lower and upper chamber, respectively, and treated with 10 µg ml −1 control IgG or anti-LILRB4 antibodies. o, Representative photographs of T cells (scale bar, 100 µm). p, T cells stained with anti-CD3 and analysed by flow cytometry. n = 4 biologically independent samples. q, Primary T cells stimulated with anti-CD3/CD28/CD137-coated beads were co-cultured with wild-type or LILRB4 KO THP-1 cells with indicated E:T ratios for 4 h (n = 3 biologically independent samples with mean and s.e.m.). Cytotoxity of leukaemia cells was determined by PI staining in flow cytometry analysis. r-u, CD8 + T cells (5 × 10 4 cells) stimulated with anti-CD3/CD28/CD137-coated beads were co-cultured with 5 × 10 3 THP-1 cells that stably express GFP and treated with 100 µg ml −1 anti-LILRB4 antibodies or control IgG for 
Extended Data Fig. 4 | Anti-LILRB4 antibodies reduce leukaemia development by restoring autologous T cells in PDX mice and inhibiting primary AML cell infiltration. a, Primary peripheral blood or bone marrow mononuclear AML cells (5 × 10 6 to 1 × 10 7 cells per mouse) from each of sixteen human patients (three shown in Fig. 1g -i, also see Supplementary Table 5 ) were injected into NSG mice followed by treatment with IgG or anti-LILRB4 antibodies (10 mg kg −1 twice a week by intravenous injection). Percentages of human CD45 + LILRB4 + AML cells collected from haematopoietic tissues including bone marrow, spleen, liver and peripheral blood 2-4 months after transplantation, as determined by flow cytometry, are shown. b, Percentages of autologous human T cells collected from haematopoietic tissues including bone marrow, spleen, liver and peripheral blood 2-4 months after transplantation, as determined by flow cytometry; and representative flow plots of CD3 + CD8 + T cells in bone marrow of mice in three PDXs. n = 8 biologically independent samples for all PDXs except AML#11 (n = 20 biologically independent samples) in a, b. c-e, Comparison of infiltration of human primary monocytic AML cells in NSG mice (n = 5 mice) after treatment with anti-LILRB4 antibody or IgG control. c, d, Primary human peripheral blood mononuclear cells from patients with monocytic AML were injected. The quantifications in c are also shown in Fig. 2l -n. e, Mouse liver cells with xenografted primary human monocytic AML cells (human CD45 + LILRB4 + cells) were injected. See Methods for definition of box plot elements in a-e. All P values from two-tailed Student's t-test.
Extended Data Fig. 8 | Detection of SHP-2-NFκB signalling and uPAR and ARG1 expression in primary human monocytic AML cells. a, LILRB4-positive or -high CD33 + AML cells (red box) and LILRB4-negative or -low CD33 + AML cells (blue box) were gated for further intracellular staining of SHP-2 phosphorylated at Y580, IKKα/β phosphorylated at S176/S180, NFκB phosphorylated at S529, uPAR and ARG1. Isotype IgG was used as negative control. Red numbers indicate MFI of LILRB4-positive or -high CD33 + AML cells; blue numbers indicate MFIs of LILRB4-negative or -low CD33 + AML cells. This experiment was repeated with eight individual patient samples with similar results. b, Quantification of individual staining in LILRB4-positive or -high CD33 + AML cells versus in LILRB4-negative or -low CD33 + AML cells. n = 8 independent patients; see Methods for definition of box plot elements. P values from two-tailed Student's t-test. c, Schematic for the mechanisms by which LILRB4 suppresses T cells and promotes leukaemia infiltration.
Extended Data Fig. 9 | Comparison of LILRB4-mediated intracellular signalling in leukaemia cells and in normal haematopoietic cells. a, Comparison of LILRB4 surface expression on normal monocytes from healthy donors (n = 25 individual donors with mean and s.e.m.) and neoplastic monocytic cells from patients with AML (n = 53 individual patients with mean and s.e.m.). b, Comparison of LILRB4 surface expression on normal monocytes from two healthy donors and on wild-type and LILRB4 KO THP-1 cells. This experiment was repeated independently three times with similar results. c, Anti-LILRB4 antibody did not affect homing ability of normal monocytes. Human normal monocytes (b) selected through CD14-positive selection. These isolated monocytes were pooled and stained by CFSE. After staining, monocytes (5 × 10 6 for each mouse) were injected into NSG mice followed immediately by antibody treatment, and then the mice (n = 4 mice, see Methods for definition of box plot elements) were killed 20 h after transplant. The number of CFSE + cells in liver, spleen and bone marrow were normalized to that in peripheral blood as determined by flow cytometry. d, e, APOE activates LILRB4 intracellular signalling in leukaemia cells. Indicated THP-1 cells and primary AML (M5) cells were serum-starved overnight and then treated with the indicated concentration of human recombinant APOE protein for the indicated time. Phospho-SHP-2, phospho-NFκB and ARG1 were examined by western blotting. f, The effect of APOE on normal monocytes or in vitro differentiated macrophages. Normal monocytes were isolated from healthy donors and macrophages were derived from these monocytes after one week of differentiation in vitro. Cells were serum-starved overnight and then treated with the indicated concentrations of human recombinant APOE protein for the indicated times. Phospho-SHP-2, phospho-NFκB and ARG1 were examined by western blotting. g, APOE induces uPAR upregulation on AML cells. Normal monocytes were isolated from healthy donors. Indicated primary AML cells and normal monocytes were serumstarved overnight and then treated with 20 µg ml −1 human recombinant APOE protein for eight hours. Surface uPAR was examined by flow cytometry. Representative flow plots are shown and MFIs are shown in top right corner (black, PBS control; red, APOE treatment). Experiments were performed three times with similar results. P values from two-tailed Student's t-test.
Extended Data Fig. 10 | Anti-LILRB4 does not affect engraftment of normal haematopoietic cells. a, LILRB4 and CD34 co-staining patterns for representative samples of human cord blood mononuclear cells (hCB MNCs). N/G, neutrophils and granulocytes; M/D, monocytes, macrophages and dendritic cells; L/P, lymphocytes, haematopoietic stem and progenitor cells. This experiment was repeated independently three times with similar results. b, Anti-LILRB4 antibody did not affect homing ability of normal haematopoietic progenitor cells. hCB MNCs (1 × 10 7 ) were injected into NSG mice followed immediately by antibody treatment, and then the mice (n = 3 mice with mean and s.e.m.) were killed 20 h after transplant. The number of CD45 + CD34 + HSCs in liver, spleen, and bone marrow were normalized to that in peripheral blood as determined by flow cytometry. c-e, Anti-LILRB4 antibodies inhibited leukaemia development in hCB-humanized NSG mice. c, Schematic of the experiment to test whether anti-LILRB4 antibody inhibits leukaemia development in hCB-humanized NSG mice. d, Leukaemia development was monitored over time by luminescence imaging. This experiment was repeated independently twice with similar results. e, Frequency of engrafted leukaemia, normal human cells, including human B cells, human myeloid cells and human T cells in peripheral blood over time and haematopoietic tissues of hCB-humanized mice at 24 days after leukaemia transplantation. n = 3 mice with mean and s.e.m. All P values from twotailed Student's t-test.
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The P values results from statistical analyses suggested that the samples sizes in our study are sufficient.
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